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bstract
Non-functioning pituitary adenoma may be totally asymptomatic and discovered “incidentally” during radiological examination for some other
ndication, or else induce tumoral signs with compression of the optic chiasm and pituitary dysfunction. Non-functioning adenomas are mainly
onadotroph, but may also be “silent”. Treatment strategy depends on initial clinical, biological, ophthalmological and radiological findings. The
resent French Society of Endocrinology Consensus work-group sought to update the pitfalls associated with hormone assay and outline a hormonal
xploration strategy for diagnosis and follow-up, without overlooking the particularities of silent adenoma. We also drew up basic rules for initial
xploration and radiological follow-up of both operated and non-operated pituitary adenomas.
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ésumé
Les adénomes hypophysaires non fonctionnels peuvent être totalement asymptomatiques et découverts de manière « incidentelle » lors
’explorations radiologiques réalisées pour d’autres indications ou bien responsable de signes tumoraux avec compressions du chiasma optique
t dysfonctions hypophysaires. Les adénomes non fonctionnels sont majoritairement des adénomes gonadotropes, mais il peut également s’agir
’adénomes dits « silencieux ». La stratégie thérapeutique de ces adénomes non fonctionnels dépend des données cliniques, biologiques, ophtal-
ologiques et radiologiques initiales. L’objectif de notre groupe de travail, dans le cadre du consensus de la Société franc¸aise d’endocrinologie, a
té de reprendre les pièges associés aux dosages hormonaux, de proposer une stratégie d’exploration hormonale au diagnostic et pour le suivi de ces
dénomes, sans oublier d’identifier la particularité des adénomes « silencieux ». Nous proposons également des règles minimales pour l’exploration
nitiale et le suivi radiologique des adénomes opérés ou non.
 2015 Elsevier Masson SAS. Tous droits réservés.
ots clés : Adénome hypophysaire non fonctionnel ; Adénomes hypophysaire gonadotrope ; Adénome hypophysaire silencieux ; Incidentalome hypophysaire ;
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menstrual cycle) or medication-related (replacement therapy atnsuffisance antehypophysaire
.  Hormonal  exploration:  what  technique  for  which
ssay?
.1.  Lactotrophs:  prolactin  assay
Prolactin is assayed by immunoanalysis using immunomet-
ic methods usually calibrated on the WHO 3rd International
tandard 84/500. The techniques are made difficult essentially
y the heterogeneity of circulating forms and by the “hook
ffect” [1,2].
.2.  Heterogeneity  of  circulating  forms
Prolactin circulates in various forms: mainly active
onomeric prolactin, but also heavy forms including macro-
rolactin, without biological action and mainly constituted by
rolactin in complex with an immunoglobulin (Ig). At the
resent time, all the immunometric methods on the market
ecognize macroprolactin, but with varying intensity, leading
o variable overestimation depending on the particular tech-
ique [3]. In case of moderately elevated prolactin contrasting
ith clinical presentation, the assay should be checked using a
echnique with little cross-reaction with macroprolactin. If the
rolactin concentration is still elevated using an immunoassay
ith low cross-reactivity for heavy form, polyethylene glycol
PEG) precipitation should be considered to screen for macro-
rolactin if the method has been properly validated by the
aboratory [1,4]. In case of positive macroprolactin screening,
nly gel-filtration chromatography can distinguish monomeric
rolactin from heavy forms and correct the initial assay estimate.
.3.  Hook  effect
In prolactinoma, prolactin concentration and adenoma vol-
me are fairly well correlated. In case of moderate elevation
espite large tumor size, an assay artifact known as the “hook
ffect” may be suspected. Here, an extremely high prolactin
oncentration saturates the tracer antibody sites before fixation
o the detection antibody/prolactin complex, leading to under-
stimation. The classic solution to the hook effect problem is
o perform the assay on a dilution of the serum sample. In case
m
u
fi
af very large macroadenoma on imaging, the clinician should
herefore inform the biologist that assay should be performed
n pure and on diluted serum.
.4.  Somatotrophs
.4.1.  GH  assay
Immunometric GH assay should be performed on a serum
ample collected in an anticoagulant-free tube [5]. The stan-
ardization of most methods following the recombinant human
H standard IS 98/574 allows results to be harmonized (1 g = 3
U) [6]. In exploring pituitary adenoma, GH can be measured
n the oral glucose tolerance test, considered effective if the
H concentration falls below 0.4 g/L (1.2 IU/L) and there-
ore requiring ultrasensitive techniques measuring low hormone
oncentrations. The methods on the markets now meet this
equirement.
.4.2. IGF-I  assay
Determining IGF-I levels requires well-codified sampling in
nticoagulant-free tubes, from a fasting patient to avoid vari-
tion with nutritional status [6]. Immunometric or competitive
ssay is performed on an acidified sample to release IGF-I and its
arrier proteins, the sites of which are secondarily saturated by
dding IGF-II. The first difficulty lies in calibration: results are
alibrated on an international standard which for many years
nvolved a poorly purified methionylated IGF-1 preparation
71 amino-acids) (WHO IRR 87/518) [7]. A new international
tandard of native IGF-I with 70 amino-acids (WHO IS 02/254)
as been prepared and communicated to all relevant manufac-
urers [7]; to date, however, only two of the six suppliers respect
his standard in their reagent packs.
The second pitfall lies in variations according, notably, to
ge, nutritional status, and hormonal status, whether physiolog-
cal (thyroid hormones, insulin and estrogens varying over theenopause). These variations require establishing reference val-
es for each assay technique in a very large population with
nely targeted inclusion criteria and stratified by age group in
dults and pubertal stage in children [8–11].
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.5.  Gonadotrophs
.5.1.  Gonadotropins
FSH and LH assay is generally performed by immunometry
n automated immunoanalysis devices using antibodies that rec-
gnize beta-chain epitopes to exclude cross-reaction with other
lycoproteins having an identical alpha sub-unit. These assays
nvolve no particular difficulty, whatever the technique or serum
oncentration.
.5.2. Testosterone
Testosterone assay in non-treated males is performed by
mmunoanalysis using competitive techniques assessing carrier
rotein-bound and physiologically active free testosterone. Pro-
ioqual external quality control showed good correlation for
alues greater than 4.8 nmol/L (1.4 ng/mL) between the vari-
us immunoanalysis methods on the market in 2007 and the
old standard of mass spectrometry coupled to liquid chro-
atography tandem mass (LC-MS/MS). Although these results
re to be interpreted with caution as a matrix effect cannot be
uled out in samples reconstituted in buffered media that are not
urely serous, they were validated in the 2010 French Society of
ndocrinology guidelines [12]. Moreover, a very recent study
onfirmed the analytic performance of the devices currently on
he market for total testosterone concentrations greater than 4
mol/L (1.2 ng/mL), enabling eugonadism and hypogonadism
o be clearly distinguished in adult males [13].
.6.  Corticotrophs
.6.1.  ACTH  assay
The fragility of ACTH requires sampling with a tube (pink
ap) containing EDTA with an added anti-protease, aprotinin.
entrifugation at exactly 4 ◦C and freezing should be per-
ormed within half an hour of blood-sampling. Also, the various
mmunometric assays on the market often lack sensitivity and are
ighly variable in the absence of any calibration standardization
14].
.6.2.  Cortisol  assay
Serum cortisol is routinely assayed on competitive immuno-
nalysis. The 2006 French health products safety agency
AFSSAPS) report [15] required manufacturers to display the
xactness of their method with respect to the gold standard LC-
S/MS and the functional detection limit locating the lower
imit of measurement. Poor reproducibility and positive or neg-
tive biases with respect to LC-MS/MS in low concentration
anges (around 71 nmol/L or 29 ng/mL) were repeatedly noted
n Probioqual reports. Thus, the low cortisol levels found with
ertain methods are to be interpreted with extreme caution, as
xactitude and precision are mandatory in low concentration
anges if corticotroph insufficiency is to be detected for assessing
he performance of the various dexamethasone suppression tests.
Urinary free cortisol is measured by competitive techniques,
hich may include an extraction phase to avoid cross-reaction
ith molecules of similar structure. Some techniques, however,
s
f
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re sufficiently specific to allow direct assay on non-extracted
rine [16].
.7.  Thyrotrophs
.7.1.  TSH
TSH assay on immunometry should have the qualities of
 third-generation assay: i.e., functional detection limit < 0.02
IU/mL [17]. Although TSH reference values in Europe, taking
ll techniques together, are classically agreed to lie between 0.4
nd 4 mIU/L, method-specific norms are recommended.
.7.2.  Free  T4
Free serum T4 assay is performed by immunoanalysis using
- or 2-step direct competition. Automated direct assay usu-
lly shows a negative bias due to equilibrium disturbance by
erum dilution and sequestration of a certain amount of hor-
one by addition of antibodies, inducing underestimation [17].
onversely, anti-T4 autoantibodies may lead to overestimation
f free T4 concentrations on 1-step methods [17]. Standardiza-
ion against the gold standard LC-MS/MS [18] should enable
armonization.
.7.3. Alpha  sub-unit  assay
A single Immunoradiometric assay measures alpha sub-unit
n serum or human plasma.
.  Interest  of  plasma  assay  of  gonadotropins  and  their
ub-units
.1.  Assessment  of  baseline  secretion
In functioning adenoma, the hormone secretion rate is a reli-
ble index of evolution. Persistent elevation signals incomplete
esection even if no residue is visible on MRI. This important
arker is generally absent in non-functioning adenoma [19].
The vast majority of clinically non-functioning pituitary ade-
omas (NFPAs) are gonadotroph, able to produce gonadotropins
r their sub-units, as demonstrated on immunocytochemistry.
owever, elevated baseline plasma dimeric FSH and/or LH is
are. Elevated free sub-unit levels (mainly , more rarely -LH)
re more common, but generally moderate.
When secretion is found, it is usually moderate and only
xceptionally associated with specific clinical signs [20–23],
indering preoperative identification of gonadotroph adenoma,
hich is generally considered “silent” and diagnosed at onset on
on-specific symptoms of tumoral syndrome (headache, visual
isorder, pituitary deficiency) or on imaging assessment for
ome other indication (“incidentaloma”: cf. dedicated article).
When baseline plasma concentrations of dimeric FSH,
imeric LH or free  sub-unit are carefully interpreted, it is
ound that half of male gonadotroph adenoma patients (as sub-
equently confirmed on immunocytochemistry or in vitro tumor
ecretion analysis) show excess secretion of FSH, LH or their
ree sub-units in quantities sufficient for plasma assay [24–28].
In pre-menopausal women, this is less common (about 30%
f cases); after the menopause, it is much harder to assess
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he “functioning” or “silent” status of gonadotroph adenoma,
iven the physiological elevation of gonadotropins and their
ub-units in women of this age. For example, FSH and LH
evels were studied in 112 gonadotroph adenoma patients; 48%
f male patients and 25% of women under 50 years of age
howed gonadotropin elevation, while serum concentrations in
ost-menopausal women were within normal limits [29].
Finally, even when initially elevated, -LH sub-unit assay is
ot predictive of residual tumor or recurrence or progression of
n existing residuum at follow-up [30].
.2.  Dynamic  assessment  of  gonadotropin  secretion
.2.1.  GnRH  stimulation
Elevated FSH and LH after GnRH stimulation was reported
n respectively 75% and 50% of cases of pituitary adenoma
31]. There is, however, no consensus as to normal GnRH test
esponse. Moreover, response varies over the menstrual cycle,
nd is non-specific, being found in other types of pituitary ade-
oma, notably prolactinoma [24,25,32,33].
.2.2. TRH  stimulation
In case of baseline FSH hypersecretion, TRH stimulates FSH
roduction in 60–70% of cases, whereas in baseline LH hyper-
ecretion, there is paradoxical LH response to TRH in only
0–30% of gonadotroph adenomas, with paradoxical LH   or
ree ß sub-unit response in 60% of cases.
If there is no baseline elevation of gonadotropins or sub-units,
aradoxical TRH stimulation response is rare.
As with the GnRH test, non-specific stimulation may be
ound in other types of adenoma [24,26,27,30,34–36].
Thus, the TRH test does not confirm diagnosis of
onadotroph adenoma; nor is it a sufficient predictive marker of
umor residuum or early recurrence during follow-up [19,30].
.2.3. Risks  of  dynamic  tests
As well as being non-contributive, dynamic GnRH and TRH
ests are not risk-free, associated pituitary apoplexy having been
eported [37–40]. However rare, the potential severity of such a
omplication, added to the lack of real benefit, means that these
ests should not be performed.
.3.  Another  marker:  chromogranin  A
Chromogranin A elevation may be found in certain pituitary
denomas [41], but assay has been shown to be of no value in
iagnosis or in follow-up [42,43].
.  Is  exploration  for  silent  pituitary  adenoma  useful?
Certain NFPAs are positive on immunohistochemistry for one
r more pituitary hormones. These are known as “silent” adeno-
as. The most frequent is gonadotroph adenoma, which will not
e dealt with here. Others, more rare, are corticotroph, soma-
otroph or thyrotroph. Can these be identified preoperatively,
head of immunohistochemistry?
a
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.1.  Hormonal  exploration  of  silent  corticotroph  adenoma
.1.1.  Free  urinary  cortisol,  cortisol  cycle,  dexamethasone
uppression  test:  is  silent  corticotroph  adenoma  really
ilent?
Are all corticotroph adenomas silent if they do not show clin-
cal signs of hypercortisolism? Such at least is the definition
pplied in most studies on this topic [44–54]. But can we be
ure that these adenomas are not in fact associated with slight
ut real abnormalities of the corticotroph axis, or in certain cases
hat Cushing’s disease has not simply been overlooked? There
ave been no large series systematically looking for signs of
light hypercortisolism associated with silent corticotroph pitu-
tary macroadenoma. Out of 2 patients with clinically silent
orticotroph adenoma, Sahli et al. reported 1 as having incom-
lete dexamethasone suppression [55]. Out of 27 patients with
ilent corticotroph macroadenoma, Webb et al. reported normal
ree urinary cortisol in both of the 2 patients tested, but they
ad been tested precisely because of the high plasma cortisol
evels randomly sampled during the day [56]. There is likely
 continuum of secretion between secreting and less secret-
ng forms of corticotroph adenoma [52,57], as in infraclinical
drenal Cushing’s syndrome [58]. What proportion of so-called
silent” corticotroph adenomas are truly silent? We do not know.
Absence of clinical hypercortisolism at a given moment is no
uarantee against hypercortisolism to come. There have in fact
een several reports of clinically silent adenomas that progressed
oward definite hypercortisolism [59–63]. May not some of these
e forms of cyclic hypercortisolism? Reports of macroadenoma
ith cyclic Cushing’s syndrome are, at any rate, few and far
etween! Prevalence of such definite hypercortisolism occurring
uring follow-up is unknown but would seem to be low, at around
 per 500 pituitary adenomas [59].
Perhaps corticotroph macroadenoma may be silenced by
poplexy. Sahin et al. published one such case report [64]. More-
ver, in series of silent corticotroph adenoma, apoplexy is a
requent presenting symptom [50,53], with a prevalence of 9
ut of 27 cases reported by Webb et al. [56] and 6 out of 24
ases reported by Cho et al. [65]. Preoperative hormonal explo-
ation, if it had been performed, would probably have revealed
orticotroph insufficiency, although this is not incompatible with
ossible hypercortisolism predating the apoplexy. Once again,
ormonal work-out, ruling out clinical hypercortisolism, is the
riterion establishing the silent nature of an adenoma.
Finally, silent corticotroph adenoma frequently conserves a
unctional corticotroph axis despite deficits in one or more pitu-
tary function [47,53], and this is probably fairly specific to
orticotroph adenoma, especially in case of slight abnormali-
ies suggestive of hypercortisolism. However, this remains to be
ssessed.
.1.2. Elevated  morning  plasma  ACTH
Several studies reported elevated plasma ACTH measuredt 8 a.m. in certain cases of silent corticotroph adenoma
48–53,56]. The proportions of patients with elevated ACTH
aried from 10% to 100%. The degree of elevation was also
ariable: usually moderate (1 to 2-fold the normal values),
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ut sometimes high (6-fold the normal values). Despite ACTH
levation, the corresponding plasma cortisol level showed no
ncrease.
Other studies reported no increase in ACTH level [44]. Two
tudies compared 8 a.m. ACTH in silent corticotroph adenoma
ersus patients with other types of non-functioning adenoma
65,66]. ACTH levels were similar in both series, and both
eported ACTH elevation in certain cases. These studies raise
he question of the significance of 8 a.m. ACTH elevation in
ilent corticotroph adenoma. The data would seem to show
hat the ACTH threshold corresponding to these adenomas is
ow.
.1.3. Dynamic  tests
Some studies reported ACTH and cortisol response to CRH in
ilent corticotroph adenoma. Tateno et al. found a clear increase
n ACTH levels with CRH (by a factor of 6 ±  4.1), although
his was not very different from the response observed in other
ypes of non-functioning adenoma (factor of 4 ±  2.9) [67]. Cor-
isol elevation was similar in both groups. Kojima et al. reported
CTH elevation after CRH stimulation [49]. From these sparse
ata, it would seem that CRH response is fairly non-specific in
on-functioning corticotroph adenoma.
ACTH levels were assessed under dexamethasone [67].
ollowing 0.5 mg dexamethasone at midnight, ACTH levels
ere slightly higher in the silent corticotroph adenoma group
13 ±  6.9 pg/mL) compared to other types of non-functioning
denoma (7 ±  1.7 pg/mL), but the difference was not significant.
Finally, 1 case of paradoxical ACTH response to TRH and
HRH has been reported [51].
.1.4. Abnormal  forms  of  ACTH
Several groups have identified abnormal ACTH [68–70] in
ilent corticotroph adenoma, in the form of large size precursors,
orresponding to abnormal maturation of proopiomelanocortin
POMC). These high-molecular-weight forms seem not to show
he biological activity of ACTH, thus explaining in some
ases the absence of hypercortisolism despite elevated ACTH.
creening for such ACTH maturation abnormalities in non-
unctioning adenoma, however, cannot yet be recommended,
bove all due to the lack of standardization of such exploration.
.2.  Hormonal  exploration  of  silent  somatotroph  adenoma
.2.1.  Is silent  somatotroph  adenoma  really  silent?
In published series and case reports, IGF-1 (and/or GH) assay
s most frequently used for apparently non-functioning pitu-
tary adenoma. It is therefore rare for a somatotroph adenoma to
e judged “silent” without hormonal support for the diagnosis,
nlike in the case of silent corticotroph adenoma, so described
urely on the basis of clinical aspect. The value of this minimal
xploration, however, is to be weighed against problems of assay
echnique, sampling procedure (single or multiple site GH sam-
ling? oral glucose tolerance test?) and choice of normal values,
otably with respect to age, which may all strongly influence
nterpretation [8,71].
n
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The major issue in silent somatotroph adenoma is the possi-
le discordance between absence of clinical signs of acromegaly
nd moderate elevation of IGF-1 or GH. In a consecutive
eries of 100 operated pituitary tumors, Wade et al. identified
4 somatotroph adenomas on immunohistochemistry, includ-
ng 11 with clear acromegaly, 4 with slight acromegaly, 8
ithout acromegaly but with elevated IGF-1, and only 1 with
either acromegaly or IGF-1 elevation [72]. In a series of 17
atients, Trouillas et al. reported 4 patients with slightly ele-
ated GH levels and 13 with normal levels (< 5 ng/mL). In a
eries of 9 patients, Pagesy et al. included patients with moder-
te IGF-1 elevation but normal GH levels [73]; certain patients
evertheless showed clinical signs of acromegaly, although dis-
rete for some. Other case reports and series found patients
ithout clinical acromegaly but with variable moderate concom-
tant IGF-1 and GH elevation [74–76] or normal IGF-1 levels
77,78].
Will such infraclinical somatotroph adenomas become more
ighly secreting? Will persistent moderate GH hypersecretion
nd up by inducing signs of acromegaly? There are no clear
nswers. Sakharova et al. reported the case of a female patient
t 8 years’ follow-up, with slightly elevated IGF-1 and no signs
f acromegaly [75].
.2.2.  Is  IGF-1  assay  enough?
Is IGF-1 assay enough, or should GH assay be associated?
hirty percent of cases of acromegaly show discordance between
GF-1 and GH levels, but it is usually IGF-1 that is elevated and
H normal [71]. Certain situations are known to lower IGF-
 levels: denutrition, kidney failure, liver failure, oral estrogen
herapy, hypothyroidism and uncontrolled diabetes [71]. Normal
GF-1 findings in such situations are therefore to be interpreted
ith caution.
Specifically in clinically silent somatotroph adenoma,
alavalapalli reported 3 cases of discordance, with normal IGF-
 and elevated GH levels [79]. Naritaka et al. reported a case of
lightly elevated GH with normal IGF-1 level, out of 3 cases with
oncomitant IGF-1 and GH assay [78]. Matsuno et al. reported
 cases of silent somatotroph adenoma, all associating normal
H and IGF-1 levels [80]. Klibanski et al. reported 1 case (out
f 3) with normal IGF-1 but elevated GH levels [74]. Prevalence
f normal GH and IGF-1 levels is probably biased by variations
n the definition of “silent”.
.2.3.  GH  assay  after  oral  glucose  tolerance  test
The GH nadir after oral glucose tolerance test (OGTT) seems
o be remarkably sensitive in diagnosing infraclinical soma-
otroph adenoma, most studies reporting abnormal suppression.
n a series of 3 silent somatotroph adenomas (2 with slightly
levated IGF-1), Klibanski et al. found elevated GH in all cases,
ot showing sufficient suppression under OGTT [74]. Pagesy
t al. included 9 patients with normal GH levels (< 5 ng/mL) but
o suppression on OGTT [73]; IGF-1 was moderately elevated.
inally, Sakharova et al. reported insufficient GH suppression on
GTT in all 3 of their patients [75]; again, IGF-1 was moderately
levated.
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.2.4.  Other  hormonal  tests
There are just a few data for GH response to TRH and GnRH.
aradoxical responses have been reported [78,80]. However,
hese data are insufficient to prove the contribution of these tests.
.  Interest  of  screening  for  pituitary  deﬁciency:
requency  and  minimum  assessment
.1.  Frequency  of  preoperative  pituitary  deﬁciency
In macroadenoma, the frequency of pituitary deficiency at
iagnosis varies between series, but with deficiency in at least
ne axis in 60–85% of cases.
The most frequent deficit is in gonadotropin, found in more
han 80% of cases, compared to 20–50% for thyrotropin and cor-
icotropin [19,81–83]. Most studies did not assess somatotropin
eficiency dynamically, but it may concern almost 70% of cases
82].
Data are scarce for non-functioning pituitary microadenoma
84,85], but it is known not to be complicated by pituitary defi-
iency, which does not need to be investigated [86,87].
.2.  Exploration  of  preoperative  pituitary  deﬁciency
Only the corticotroph axis should undergo dynamic explo-
ation at diagnosis of non-functioning pituitary macroadenoma.
lthough very low 8 a.m. cortisol levels indicate pituitary defi-
iency, a short synacthen test or insulin tolerance test, depending
n general health status, is recommended.
The thyrotroph axis should undergo static exploration, with
rd generation TSH assay and free T4 assay.
For the gonadotroph sector, no biological exploration is
equired in women with spontaneously normal menstrual cycle;
n case of amenorrhea, on the other hand, even in women of
enopausal age, FSH assay can guide diagnosis toward a periph-
ral etiology or else gonadotropin deficiency.
In male subjects, LH, FSH and plasma total testosterone
hould be assayed to screen for associated gonadotroph defi-
iency.
We have no clinical data relating to the interest of preoperative
creening for somatotroph deficiency.
.3.  Interest  of  screening  for  pituitary  deﬁciency
Preoperative screening for pituitary deficiency enables
dapted replacement therapy to be initiated to improve general
ealth status ahead of surgery and avoid intraoperative acute
orticotroph deficiency.
The peri-operative corticotroph replacement protocol may
e guided by a deficit detected preoperatively. In case
f preoperatively proven corticotroph deficiency, 48 hours’
upraphysiological corticotherapy should be administered peri-
peratively (e.g., hydrocortisone, 50 mg every 8 hours on D0,
hen 25 mg every 8 hours on D1, and 25 mg at 8 a.m. on D2). In
ase of intact preoperative corticotroph function and if selective
denoma resection is feasible, peri-operative glucocorticoids are
nnecessary [88].
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Moreover, knowledge of preoperative pituitary deficiency
an influence treatment options. Pituitary adenoma resection
mproves pituitary function in 30% of cases and achieves nor-
alization in 20%, with only 1% of aggravation and unchanged
unction in 50% [81–83]. Surgery may thus be indicated in young
atients even in the absence of visual disorder, and especially in
omen hoping for pregnancy (see article on Incidentaloma).
.4.  Postoperative  follow-up  of  pituitary  function
In the immediate (7–10 days) postoperative period, the focus
hould be on the assessment and correction of corticotroph pitu-
tary deficiency and on screening for diabetes insipidus.
The corticotroph axis recovers very quickly postoperatively,
nd serum cortisol assay at 8 a.m. 3–7 days after surgery identi-
es patients who have recovered normal corticotroph function.
hus, cortisol < 100 nmol/L suggests presence and > 450 nmol/L
bsence of corticotroph deficiency; intermediate findings require
omplementary tests. The short synacthen test is not reliable at
hese early stages; only the insulin tolerance test shows 100%
ensitivity and specificity, but is often precluded by general
ealth status, although it remains the test of choice, often per-
ormed 4–6 weeks after surgery, with minimal corticotroph
eplacement (15–20 mg per day) in the meanwhile [88].
An alternative may be to systematically perform dynamic
xploration 4–6 weeks post-surgery, reducing hospital stay
nd facilitating practical organization in certain centers [89].
oreover, it identifies patients with delayed corticotroph axis
ecovery [88].
The literature data suggest that corticotroph deficiency may
esolve within 3 months of surgery [90,91]; it is therefore rec-
mmended to repeat corticotroph axis exploration at 3 months
n case of initial deficiency [88].
Likewise, the thyrotroph and gonadotroph axes should be
ssessed during the postoperative period. However, there are
ew data indicating the ideal frequency and timing for such
xploration. Although systematically performed 4–6 weeks after
urgery, long-term predictive value is unknown. In case of initial
eficiency, it is therefore recommended to repeat exploration at
, 6 and 12 months [19].
In the absence of postoperative pituitary deficiency, there
re no data supporting exploration for secondary onset in the
bsence of residual tumor; in case of tumoral recurrence or
esidual tumor progression, on the other hand, further pituitary
xploration is recommended, similar to that performed at initial
iagnosis, to screen for onset of deficiency, to be repeated at least
nce yearly in the absence of complementary treatment [81].
In case of complementary radiation therapy, pituitary func-
ion exploration should be systematic, at least once yearly for at
east 10 years, due to the increased risk of onset of deficiency
uring follow-up [19,81].
.  What  neuroradiological  exploration?Positive diagnosis is based on MRI, which is the reference
xamination for the sellar region. Gadolinium injection should
e associated. The usual contraindications (pregnancy, pace-
aker, etc.) are to be respected.
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.1.  Types  of  acquisition
Coronal acquisitions should be taken perpendicular to the
icallosal plane. MRI should comprise at least:
 sagittal spin-echo (SE) T1-weighted, coronal T1 and T2-
weighted sequences and a gadolinium-enhanced (or, ideally
volumetric gadolinium-enhanced with coronal reconstruction
and lesion volume assessment) T1-SE acquisition;
 thin slices (≤  3 mm) with elevated matrix;
 complementary sequences according to the circumstances:
dynamic, axial T1-SE fat-sat, high-resolution coronal COR
T1-SE, high-resolution coronal SAG T1-SE.
Secondary CT-scan without contrast enhancement may
ssess skull-base lesions or explore possible tumoral calcifica-
ion in differential diagnosis.
.2.  MRI  results
In macroadenoma, MRI finds a mass centered on the sella
urcica, which is enlarged, with T1/T2 signal varying according
o necrotic and/or hemorrhagic areas, and possible fluid level.
ptake is usually not intense and less than in the healthy ante-
ior pituitary parenchyma. Multiple microcysts on T2-weighted
equences suggest silent corticotroph adenoma [92].
Extension should be assessed:
 superior extension toward the optic pathways: treatment
depending mainly on visual disorder, the relation between
the superior pole of the tumor and the optic chiasm should be
carefully assessed (chiasmal displacement or compression,
hypersignal on T2);
 lateral extension into the cavernous sinus, assessing per-
centage internal carotid enclosure (caliber being generally
conserved), aspect of the medial venous plexus of the cav-
ernous sinus and visualization of the medial wall on 3T MRI;
the Knops classification may be used: extension beyond the
lateral intercarotid line showing 95% predictive value for cav-
ernous sinus invasion;
 inferior extension in the sphenoidal sinus, with sellar floor
analysis;
 posterior extension, with clivus analysis.
The pituitary stalk, the posterior pituitary lobe and residual
ealthy pituitary parenchyma should be located.
Differential diagnosis is dealt with in the article on inciden-
aloma.
Diagnosis is mainly based on sella tunica size, degree of
umor uptake, presence of calcification, and presence of intrale-
ional fluid level.
Imaging follow-up, after surgery, in case of severe or pro-
ressive visual disorder.In case of immediate postoperative aggravation, CT without
nhancement explores for surgery-site edema.
Early MRI in the first postoperative days or weeks is reserved
or complications (e.g., rhinorrhea). MRI detects cerebrospinal
[rinologie 76 (2015) 201–209 207
uid leakage in slightly more than 75% of cases [93,94], on
pecific highly T2-weighted high-resolution coronal slices of at
east 2 mm, ideally on 3T MRI.
In classical postoperative surveillance programs, MRI is
lways performed according to the same protocol (the same as
he initial protocol), ideally on the same machine or with data
ntegrated into the institution’s picture-archiving and communi-
ation system (PACS) at month 3 and 12 and then yearly.
In simple surveillance, yearly MRI follows the initial pro-
ocol, with comparison of lesion volume. It is often useful to
ompare all examinations rather than only the last two, as tumor
rowth is usually minimal.
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